MYD88 and neoplasm: In this review, we gathered critical evidence of MyD88 in regulating tumors and immune microenvironment, summarize recent research progress on MyD88 inhibitors, and reveal that residue ARG288 is highly likely to be an anti-tumor binding site between Myd88 protein and inhibitors.